PTIX Protagenic Therapeutics, Inc.\new
Pharmaceutical Preparations · OTC · SEC CIK 1022899 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY168.9%
TTM EPS YoY138.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA155.7%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets50.8%
Debt / equity0.00x
Current ratio0.16x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.30x
Accruals ratio201.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $901,896 | $376,740 | $3.84M | $3.06M | $1.59M |
| SG&A expense | $332,393 | $77,530 | $1.76M | $1.21M | $1.97M |
| Operating income | -$4.50M | -$2.59M | -$5.70M | -$4.53M | -$3.56M |
| Interest expense | — | — | — | $107,682 | $137,456 |
| Pretax income | $1.37M | -$3.59M | -$5.53M | -$5.00M | -$3.56M |
| Net income | $1.37M | -$3.59M | -$5.53M | -$5.00M | -$3.56M |
| EBITDA | -$4.45M | — | -$5.65M | -$4.50M | -$3.56M |
| EPS (basic) | 0.59 | -0.67 | -1.13 | -1.15 | -0.82 |
| EPS (diluted) | 0.59 | -0.67 | -1.13 | -1.15 | -0.82 |
| Weighted avg. shares (diluted) | 2.33M | 5.37M | 4.90M | 4.34M | 4.32M |
| Banking | |||||
| Net interest income | -$1.50M | -$1.04M | — | — | — |
| Balance sheet | |||||
| Cash & equivalents | $1.51M | $14,531 | $79,568 | $1.29M | $215,189 |
| Short-term investments | — | — | — | $2.77M | $7.76M |
| Inventory | — | $1,038 | — | — | — |
| Current assets | $1.54M | $89,093 | $1.88M | $4.20M | $8.04M |
| PP&E, net | $14,556 | $60,474 | $73,046 | $123,332 | $1,775 |
| Intangibles | $2.09M | — | — | — | — |
| Total assets | $3.65M | $89,093 | $1.96M | $4.32M | $8.04M |
| Current liabilities | $1.03M | $5.04M | $942,759 | $655,252 | $1.12M |
| Total liabilities | $1.03M | $5.04M | $942,759 | $655,252 | $1.12M |
| Shareholders' equity | $2.62M | -$4.95M | -$3.32M | $3.67M | $6.92M |
| Shares outstanding | 1.81M | 5.80M | 517,257 | 4.44M | 4.32M |
| Cash flow statement | |||||
| Operating cash flow | -$2.81M | -$1.77M | -$4.22M | -$3.70M | -$1.99M |
| Capital expenditure | $3,297 | — | — | $149,775 | $1,805 |
| Free cash flow | -$2.81M | — | — | -$3.85M | -$2.00M |
| Investing cash flow | $629,883 | — | $2.80M | $4.78M | $1.60M |
| Financing cash flow | $3.87M | $1.81M | $1.96M | — | — |
| Depreciation & amortization | $49,215 | — | $50,286 | $28,218 | $30 |
| Stock-based compensation | $418,589 | — | $923,139 | $666,828 | $864,681 |
Free plan shows the latest 5 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.